3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
5
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Myeloid
2
Conditions
Hematologic Neoplasms
4
Primary Myelofibrosis
3
Myeloproliferative Disorders
2
Solid Tumor
1
Neoplasms
1
Interventions
ruxolitinib
21
Azacitidine
5
ponatinib
4
parsaclisib
4
nilotinib
4
itacitinib
4
anagrelide
3
Phlebotomy
3
Imatinib Mesylate
3
INCB039110
3
Aspirin
3
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
3
venetoclax
2
pemigatinib
2
luspatercept
2
imetelstat
2
givinostat hydrochloride
2
givinostat
2
fedratinib
2
asciminib
2
INCB057643
2
Gemcitabine
2
GRN163L peptide
2
spartalizumab
1
sonidegib
1
selinexor
1
sabatolimab
1
rucaparib
1
pembrolizumab
1
navitoclax
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Myeloproliferative Disorders
×
fedratinib
×
Clear all
NCT03952039
2025-08-28
FREEDOM2
Celgene
Phase 3
Completed
202 enrolled
23 charts
NCT03755518
2024-12-12
FREEDOM
Celgene
Phase 3
Terminated
38 enrolled
23 charts